Диагностика и таргетная терапия ALK, ROS1, RET и NTRKпозитивного немелкоклеточного рака легкого. Резолюция совета экспертовALK-, ROS1-, RET-, and NTRK-positive non-small cell lung cancer: diagnosis and targeted therapy

of clinical trials dedicated to oncourology have begun, using lncRNA as new biomarkers or treatments

an inflammatory response of astrocytes. Moreover, PTEN siRNA counteracted the inflammatory response induced by OGD

RNAs), which are RNA molecules that are not translated into proteins. The best known of these are microRNAs (mi

. Among all founded lncRNA-based therapeutics and non-invasive diagnostic tools, nuclear enriched abundant

RNAs) as dynamic modifiers in the pathogenesis of various diseases. MiRNAs are a separate class of RNA molecules

Модификаторы хроматина в патогенезе эндометриозаРНК», «endometriosis», «chromatin modifiers», «histone acetylation», «DNA methylation», «microRNA». Оценка статей

Стриктурирующая форма болезни Крона тонкой кишки (обзор литературы)Stricturing Small Bowel Crohn’s Disease (Literature Review)

Острая спаечная кишечная непроходимость: сравнительный анализ открытых и лапароскопических операцийAcute Adhesive Small Bowel Obstruction: a Comparative Analysis of Open and Laparoscopic Surgery